Showing 5131-5140 of 8843 results for "".
- National Eczema Association's New Campaign Exposes The “Real Eczema”https://practicaldermatology.com/news/national-eczema-associations-new-campaign-exposes-the-real-eczema/2460160/October's Eczema Awareness Month efforts will focus on unhiding the realities of eczema with the National Eczema Association's (NEA) #TheRealEczema campaign. The new campaign includes a video, "The Real Eczema," featur
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Neutrogena’s Newest Collection Addresses Dull, Uneven Skinhttps://practicaldermatology.com/news/neutrogenas-newest-collection-addresses-dull-uneven-skin/2460157/Nearly two-thirds (66 percent) of U.S. millennial women age 23-38 have noticed a shift in their skin's brightness, according to a poll of more 1,100 U.S. women aged 18 and older sponsored by Neutrogena. Neutrogena’s new four-part collection,
- Study: Recell System Plus Dermabrasion Speeds Acne Scar Healinghttps://practicaldermatology.com/news/study-recell-system-plus-dermabrasion-speeds-acne-scar-healing/2460154/When combined with dermabrasion, the RECELL Autologous Cell Harvesting Device speeds the healing of facial acne scars, according to a study in Aesthetic Plastic Surgery. The RECELL System uses a small
- L'Oréal USA Announces Winners Of 2019 Women In Digital Next Generation Awardshttps://practicaldermatology.com/news/loreal-usa-announces-winners-of-2019-women-in-digital-next-generation-awards/2460152/L'Oréal USA announced the winners of the 2019 Women in Digital NEXT Generation Awards. The three winners, each of whom will receive $25,000 in grant funding, include Mandi Nyambi and Lanya Olmsted, the co-founders of Baalm, an
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the
- With Fibrocell Acquisition, Castle Creek Expands Late-Stage EB Pipelinehttps://practicaldermatology.com/news/with-fibrocell-acquisition-castle-creek-expands-late-stage-eb-pipeline/2460149/Castle Creek Pharmaceutical Holdings, Inc. acquired Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings’ subsidiary,
- Increased Adherence, Symptom Improvement Seen When Psoriasis Patients Switch to IL-17 Blockershttps://practicaldermatology.com/news/increased-adherence-symptom-improvement-seen-when-psoriasis-patients-switch-to-il-17-blockers/2460147/New data points to increased adherence and improvement in symptoms for psoriasis patients who switch to interleukin-17 inhibitors. The study, which was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime, was presented at the National Association of Specialty Pharma
- Aczone 7.5% Gel Now Approved Down to Age 9https://practicaldermatology.com/news/aczone-75-gel-now-approved-down-to-age-9/2460144/The FDA has approved the expanded indication for Almirall’s Aczone® 7.5% Gel to include patients aged 9-11. Aczone 7.5% Gel was previously approved in February 2016 to treat inflammatory and non-inflammatory acne in patients 12 and older. The expanded approval was based
- Newly Created Lancer Endowed Chair of Dermatology Honors Dr. Richard Rox Andersonhttps://practicaldermatology.com/news/newly-created-lancer-endowed-chair-of-dermatology-honors-dr-richard-rox-anderson/2460141/The inaugural Lancer Endowed Chair of Dermatology at Massachusetts General Hospital (MGH) is Richard Rox Anderson, MD, director of the MGH Wellman Center for Photomedicine. The Lancer Endowed Chair was announced on Sep. 4, 2019 by Harold Lancer, MD at the Paul S. Russell,